Premium
Predictive value of early 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high‐dose chemotherapy
Author(s) -
Castagna Luca,
Bramanti Stefania,
Balzarotti Monica,
Sarina Barbara,
Todisco Elisabetta,
Anastasia Antonella,
Magagnoli Massimo,
Mazza Rita,
Nozza Andrea,
Giordano Laura,
Rodari Marcello,
Rinifilo Eva,
Chiti Arturo,
Santoro Armando
Publication year - 2009
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07645.x
Subject(s) - medicine , chemotherapy , positron emission tomography , fluorodeoxyglucose , lymphoma , refractory (planetary science) , salvage therapy , abvd , nuclear medicine , hodgkin's lymphoma , radiology , cyclophosphamide , vincristine , physics , astrobiology
Summary This retrospective study evaluated whether early 2‐[fluorine‐18]fluoro‐2‐deoxy‐D‐glucose positron emission tomography (FDG‐PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high‐dose chemotherapy (HDC). Twenty‐four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2‐year progression‐free survival was 93% vs. 10% for patients with negative and positive PET2, respectively ( P < 0.001). This study shows that interim PET can predict the outcome after high‐dose chemotherapy in HL patients.